PharmaLectures.com

Courses › Regulatory affairs by region › European Union: Paediatric, orphan and hybrid applications a generic company actually meets

European Union: Paediatric, orphan and hybrid applications a generic company actually meets

Your hybrid dossiers reach validation with paediatric and orphan status settled.

  • 6 audio modulesthree lengths each
  • 1 h to 5 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, QA, BDwho it is written for

Why this training matters

The dossier is bought, the hybrid is drafted, and validation questions arrive about a paediatric plan nobody checked. Then someone finds an orphan medicine whose market protection is still running. The work waits while a competitor files first.

What changes after this course

Your team settles the paediatric and orphan position before a line of the dossier is drafted, and files the hybrid with the reasoning ready. You hold a certificate for every learner and a training record per person for the day an inspector asks.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory team answers the paediatric question in the project meeting instead of promising to check. They read Article 9 of Regulation (EC) No 1901/2006 against the legal basis, see that an Article 10 product sits outside the Article 7 and 8 duties, and request a waiver only when a plan is due. The timeline stops carrying a paediatric gap that was never there.

Business development reads the Community Register of Orphan Medicinal Products before a licensing call, not after. Regulation (EC) No 141/2000 gives ten years of market protection, and Article 8 sets out the derogations. The team knows which could open the door and which cannot, and the Committee for Orphan Medicinal Products opinion becomes one line on the due diligence list.

Authors drafting under Article 10(3) of Directive 2001/83/EC know which non-clinical and clinical results sit beside the reference product data, and why. A changed strength, route or indication is justified with the right studies, set out as such in the dossier. The first draft no longer reads like a pure generic.

Quality assurance gets a checklist for the hybrid file: which clinical evidence Article 10(3) calls for, whether the data trace back to source, and where the Article 9 statement sits. Gaps are caught in the internal review, not in the health authority's letter or at an inspection.

Who needs this training

  • Regulatory Affairs Manager

    Asked in the project meeting whether the new product needs a paediatric plan, they answer from Article 9 of Regulation (EC) No 1901/2006 and record the legal basis in the file.

  • Business Development Lead

    Before signing a licensing deal, they check orphan status and count the ten-year market protection to a launch date, so the company does not buy a product that cannot be authorised yet.

  • Quality Assurance Specialist

    Reviewing a hybrid file before submission, they hold a checklist of the non-clinical and clinical data Article 10(3) requires and return gaps to the author, not to the authority.

  • Head of Regulatory Strategy

    At the start of a project, they choose between a pure generic and an Article 10(3) hybrid, and set the paediatric and orphan position that the whole timeline rests on.

Roles: Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Explain in writing why Article 9 of Regulation (EC) No 1901/2006 exempts a given Article 10 product from a Paediatric Investigation Plan.
  2. Draft a product-specific waiver request that cites the Article 11 grounds and is ready for the Paediatric Committee.
  3. Check whether a condition appears on the Paediatric Committee class waiver list before planning any paediatric study.
  4. Calculate the end date of the ten-year market protection of an authorised orphan medicine and name the three derogations.
  5. Decide whether a product needs an Article 10(1) generic or an Article 10(3) hybrid application and record the reason.
  6. Review a hybrid dossier for missing non-clinical and clinical data before submission.
  7. Prepare a go or no-go note for business development on a generic orphan candidate.

What the company gets

  • Hybrid applications reach validation with the paediatric and orphan position already confirmed and written into the file.
  • Business development stops spending time on candidates that orphan market protection blocks, because the status check happens before the dossier is bought.
  • Regulatory affairs and quality assurance share one list of the data an Article 10(3) hybrid needs, so gaps are found internally.
  • Each learner holds a certificate and a per-person training record, so an inspector gets a straight answer on who was trained.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 6 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 30 min25 min a module, for regulatory, quality and business-development staff
Expanded5 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing1 h
Regulatory affairsStandard2 h 30 min
Quality assurance and Qualified PersonStandard2 h 30 min

Course outline: 6 modules

6 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Place your generic correctly under Regulation (EC) No 1901/2006 timelines

    • Why Article 9 of Regulation (EC) No 1901/2006 keeps your Article 10 generic outside the plan duty.
    • How to tell on day one whether a product faces Article 7 or 8, so the timeline has no paediatric gap.
    • The one-line answer to give the project team when they ask whether paediatric rules hit your timeline.
  2. 2Win a product-specific waiver from the Paediatric Investigation Plan duty

    • How to word a product-specific waiver request so the Paediatric Committee has little to query.
    • When a class waiver by condition covers your product and when it does not.
    • The three grounds in Article 11 that justify a waiver, so you drop paediatric trials nobody needs.
  3. 3Clear orphan market protection hurdles before generic entry

    • Where to check a product's orphan status before a licensing call, so you know who holds the protection.
    • How to count the ten-year market protection under Regulation (EC) No 141/2000 to a firm launch date.
    • When the three derogations in Article 8 let a similar product in, and when they do not.
  4. 4Draft Article 10(3) hybrid applications that pass validation

    • Why a changed strength, route or indication moves you from Article 10(1) to Article 10(3).
    • How to choose between a generic and a hybrid route before the first study is commissioned.
    • The non-clinical and clinical results that Article 10(3) expects next to the reference product data.
  5. 5Stop validation delays from applying paediatric rules to generics wrongly

    • What to do when validation questions ask for a paediatric plan your Article 10 product never needed.
    • How to state the Article 9 position in Module 1 so the validator does not ask for a plan.
    • Why a hybrid with missing clinical data stalls at validation, and the check that catches the gap first.
  6. 6Align business development deals with the orphan regulations

    • The questions to put to a seller before business development signs for a dossier.
    • How to turn a paediatric and orphan status check into a one-page go or no-go for the portfolio meeting.
    • When to walk away from a candidate because orphan protection blocks it, before the dossier is bought.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

6 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h in the briefing length and 5 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 54 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team